Observational Study to follow up patients enrolled in Prospective clinical study of comprehensive genomic profiling for patients with chemotherapy-naive advanced cancer (FIRST-Dx trial).

Muto Manabu0 sites180 target enrollmentJune 9, 2022

ConditionsChemotherapy-naive adult patients with advanced cancer (GI, Lung, Breast, GYN, Melanoma)

Overview

Phase: 未知
Intervention: Not specified
Conditions: Chemotherapy-naive adult patients with advanced cancer (GI, Lung, Breast, GYN, Melanoma)
Sponsor: Muto Manabu
Enrollment: 180
Status: Recruiting
Last Updated: 2 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

No summary available.

Registry

who.int

Start Date

June 9, 2022

End Date

TBD

Last Updated

2 years ago

Study Type

Observational

Investigators

Sponsor

Muto Manabu

Eligibility Criteria

Inclusion Criteria

•1\. Registered in FIRST\-Dx trial, and underwent F1CDx.
•2\. Written informed consent.

Exclusion Criteria

•1\. Withdrawal of informed consent.
•2\. Registered in FIRST\-Dx trial, but failed in F1CDx.
•3\. Inappropriate case judged by investigators.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting

Not Applicable

An Observational Follow-up Study for Subjects Receiving Salvage Therapy After Previous Treatment in a Visilizumab Study for Intravenous Steroid-Refractory Ulcerative Colitis - RESTORE™ SIntravenous Steroid-Refractory Ulcerative Colitis (IVSR-UC)MedDRA version: 9.0Level: LLTClassification code 10045365

EUCTR2005-004105-28-GRPDL BioPharma, Inc.300

Active, not recruiting

Not Applicable

An Observational Follow-up Study for Subjects Receiving Salvage Therapy After Previous Treatment in a Visilizumab Study for Intravenous Steroid-Refractory Ulcerative ColitisIntravenous Steroid-Refractory Ulcerative Colitis (IVSR-UC)MedDRA version: 9.0Level: LLTClassification code 10045365

EUCTR2005-004105-28-NLPDL BioPharma, Inc300

Active, not recruiting

Not Applicable

An Observational Follow-up Study for Subjects Receiving Salvage Therapy After Previous Treatment in a Visilizumab Study for Intravenous Steroid-Refractory Ulcerative Colitis - RESTORE™ S

EUCTR2005-004105-28-DEPDL BioPharma, Inc.300

Active, not recruiting

Not Applicable

An Observational Follow-up Study for Subjects Receiving Salvage Therapy After Previous Treatment in a Visilizumab Study for Intravenous Steroid-Refractory Ulcerative Colitis - RESTORE™ S

EUCTR2005-004105-28-FRPDL BioPharma, Inc.300

Active, not recruiting

Not Applicable

An Observational Follow-up Study for Subjects Receiving Salvage Therapy After Previous Treatment in a Visilizumab Study for Intravenous Steroid-Refractory Ulcerative Colitis.

EUCTR2005-004105-28-GBPDL BioPharma, Inc.300